BKI-1369
BKI-1369 is a bumped kinase inhibitor (BKI) . BKI-1369 increases human Ether-a-go-go-related gene (hERG) -inhibitory activity with an IC50 of 1.52 μM. BKI-1369 reduces the parasite burden and diseases severity in the gnotobiotic pig model. BKI-1369 has been well characterized for potency, stability, metabolism, toxicity, pharmacokinetics and is potent against C. parvum in infected mice and calves[1].
Product Specifications
CAS Number
1951431-22-3
UNSPSC
12352005
Target
Parasite
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-immunoregulation
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/bki-1369.html
Purity
98.77
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
NC1=C2C(N(CC3CCN(C)CC3)N=C2C4=CC=C5N=C(OCC)C=CC5=C4)=NC=N1
Molecular Formula
C23H27N7O
Molecular Weight
417.51
References & Citations
Cryptosporidium hominis
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
C13orf18 (RUBCNL) (NM_001286762) Human Tagged ORF Clone
